These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 12690203)

  • 1. Polyubiquitination of p53 by a ubiquitin ligase activity of p300.
    Grossman SR; Deato ME; Brignone C; Chan HM; Kung AL; Tagami H; Nakatani Y; Livingston DM
    Science; 2003 Apr; 300(5617):342-4. PubMed ID: 12690203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53: evidence for the role of p300 in integrating ubiquitination and proteolysis.
    Zhu Q; Yao J; Wani G; Wani MA; Wani AA
    J Biol Chem; 2001 Aug; 276(32):29695-701. PubMed ID: 11340074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability.
    Argentini M; Barboule N; Wasylyk B
    Oncogene; 2001 Mar; 20(11):1267-75. PubMed ID: 11313871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
    Honda R; Yasuda H
    EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of p53 degradation by Mdm2 acetylation.
    Wang X; Taplick J; Geva N; Oren M
    FEBS Lett; 2004 Mar; 561(1-3):195-201. PubMed ID: 15013777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p300/MDM2 complexes participate in MDM2-mediated p53 degradation.
    Grossman SR; Perez M; Kung AL; Joseph M; Mansur C; Xiao ZX; Kumar S; Howley PM; Livingston DM
    Mol Cell; 1998 Oct; 2(4):405-15. PubMed ID: 9809062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
    Honda R; Tanaka H; Yasuda H
    FEBS Lett; 1997 Dec; 420(1):25-7. PubMed ID: 9450543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2.
    Matt T; Martinez-Yamout MA; Dyson HJ; Wright PE
    Biochem J; 2004 Aug; 381(Pt 3):685-91. PubMed ID: 15154850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation.
    Jin Y; Zeng SX; Lee H; Lu H
    J Biol Chem; 2004 May; 279(19):20035-43. PubMed ID: 14769800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression.
    Wadgaonkar R; Collins T
    J Biol Chem; 1999 May; 274(20):13760-7. PubMed ID: 10318779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function.
    Thomas A; White E
    Genes Dev; 1998 Jul; 12(13):1975-85. PubMed ID: 9649502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53.
    Li Z; Day CP; Yang JY; Tsai WB; Lozano G; Shih HM; Hung MC
    Cancer Res; 2004 Dec; 64(24):9080-5. PubMed ID: 15604276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDMX inhibits the p300/CBP-mediated acetylation of p53.
    Sabbatini P; McCormick F
    DNA Cell Biol; 2002 Jul; 21(7):519-25. PubMed ID: 12162806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
    Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
    Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2.
    Li M; Brooks CL; Wu-Baer F; Chen D; Baer R; Gu W
    Science; 2003 Dec; 302(5652):1972-5. PubMed ID: 14671306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human homologue of yeast Rad23 protein A interacts with p300/cyclic AMP-responsive element binding (CREB)-binding protein to down-regulate transcriptional activity of p53.
    Zhu Q; Wani G; Wani MA; Wani AA
    Cancer Res; 2001 Jan; 61(1):64-70. PubMed ID: 11196199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.
    Fang S; Jensen JP; Ludwig RL; Vousden KH; Weissman AM
    J Biol Chem; 2000 Mar; 275(12):8945-51. PubMed ID: 10722742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
    Xirodimas D; Saville MK; Edling C; Lane DP; Laín S
    Oncogene; 2001 Aug; 20(36):4972-83. PubMed ID: 11526482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.
    Zhou BP; Liao Y; Xia W; Zou Y; Spohn B; Hung MC
    Nat Cell Biol; 2001 Nov; 3(11):973-82. PubMed ID: 11715018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of an E1A-CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300.
    O'Connor MJ; Zimmermann H; Nielsen S; Bernard HU; Kouzarides T
    J Virol; 1999 May; 73(5):3574-81. PubMed ID: 10196247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.